MacroGenics logo
MacroGenics
MGNX | NASDAQ
Chart Builder DCF Calculator
$2.17
-$0.03 (-1.36%)
At close: Nov 16, 2026, 4:00 PM ET
$2.14
-$0.03 (-1.38%)
After-hours: Nov 16, 2026, 7:30 PM ET

MacroGenics Company Profile

Company profile explained

Company Profile

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Key Executives

Name Position
Eric Blasius Risser Chief Executive Officer, President & Director
Araba Lamouse-Smith Vice President of Technical Operations
Beth Smith Vice President, Controller & Treasurer
Ezio Bonvini Senior Vice President of Research & Chief Scientific Officer
Frank George Perabo FEBU Vice President & Interim Head of Clinical Development
Harish Krishnaswamy Senior Vice President of Business Development & Portfolio Planning
James Karrels Senior VP & CFO
Jeffrey Stuart Peters Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer
Steve Harig Senior Vice President of Human Resources

Latest SEC Filings

Date Type Title
Oct 23, 2026 8-K Current Report
Oct 07, 2026 4 Filing
Sep 03, 2026 S-8 Filing
Sep 03, 2026 8-K/A [Amend] Current Report
Aug 20, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 14, 2026 10-Q Quarterly Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 8-K Current Report
Aug 03, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
MacroGenics
MacroGenics logo
Country United States
IPO Date Oct 10, 2013
Industry Biotechnology
Sector Healthcare
Employees 293
CEO Eric Risser

Contact Details

9704 Medical Center Drive Rockville, Maryland 20850 United States

Stock Details

Ticker Symbol MGNX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001125345
CUSIP Number 556099109
ISIN Number US5560991094
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.